Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Cortese discusses how new research can drive changes to ADHD clinical trials.
Treatment for attention deficit-hyperactivity disorder (ADHD) is best as a combination of pharmacologic options with non-pharmacologic therapy.
However, researchers continue to examine the best practices for this patient population in regard to what treatment options are optimal and in what order.
Recently, in an article posted in the New England Journal of Medicine, Samuele Cortese, MD, PhD, Professor of Child and Adolescent Psychiatry, University of Southampton, examined the current state of pharmacologic treatment for ADHD.
Cortese reviewed current literature and found geographic variation in the prevalence of medication use for the disorder in 2014 ranged from 0.39% in France to 5.56% in the US for children and adolescents. The range was also 0.01% in Hong Kong to 2.11% in the US for adults.
Overall, the prevalence of ADHD medication use was substantially lower than the estimated prevalence of ADHD from 2001-2015.
Cortese also examined the efficacy and effectiveness of the ADHD medications and found the effects of ADHD medications on measures of quality of life have correlated inconsistently with abatement of ADHD symptoms.
In an interview with HCPLive®, Cortese explained how the study could drive different practices in ADHD treatment patterns and how clinical trials for new and existing ADHD medications could be changed.